Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dulaglutide (Trulicity) vs Exenatide (Byetta / Bydureon)
An educational, source-based comparison of Dulaglutide (Trulicity) and Exenatide (Byetta / Bydureon) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
First-in-class GLP-1 receptor agonist for type 2 diabetes.
Synthetic version of exendin-4 (originally from Gila monster saliva). Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and increase satiety.
- Type 2 diabetes
- Weight management (off-label)
- • FDA-approved.
- • Nausea common; pancreatitis warning.
Dulaglutide (Trulicity) vs Exenatide (Byetta / Bydureon) — Key differences
- Class: Dulaglutide (Trulicity) is classified as GLP-1 Agonist · Metabolic, while Exenatide (Byetta / Bydureon) is GLP-1 Agonist · Metabolic.
- Primary research focus: Dulaglutide (Trulicity) — type 2 diabetes; Exenatide (Byetta / Bydureon) — type 2 diabetes.
- Tag: FDA-Approved · Metabolic vs FDA-Approved · Metabolic.